Art. -Nr.: HY-13018

MRT67307

Name: MRT67307
Brand: MedChemExpress
SKU: HY-13018
Price: 96.00 USD
Availability: InStock
Rating: 5 (29 reviews)

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC₅₀s of 160 and 19 nM, respectively. MRT67307 also inhibits ULK1 and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.56%
CAS. Nr.: 1190378-57-4
Formel: C₂₆H₃₆N₆O₂
Molecular Weight:464.60

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MRT67307 Chemical Structure

CAS. Nr.: 1190378-57-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC₅₀s of 160 and 19 nM, respectively^[1]. MRT67307 also inhibits ULK1 and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells^[2].

IC₅₀ & Target

^[1]^[2]

TBK1

19 nM (IC₅₀, at 0.1 mM ATP)

IKKε

160 nM (IC₅₀, at 0.1 mM ATP)

ULK2

38 nM (IC₅₀)

ULK1

45 nM (IC₅₀)

Autophagy

Alle IKK Isoform-spezifische Produkte anzeigen :

Alle ULK Isoform-spezifische Produkte anzeigen :

ULK1
ULK2

In Vitro

MRT67307 inhibits IKK and TBK1 with IC₅₀ values of 160 and 19 nM when assayed at 0.1 mM ATP in vitro, but did not inhibit IKKα or IKKβ even at 10 μM^[1].
MRT67307 (2 μM) prevents the phosphorylation of IRF3 in bone-marrow-derived macrophages (BMDMs). MRT67307 (2 μM) dose not suppresse the activation of JNK or p38 MAPK by poly(I:C)^[1].
MRT67307 (1 nM-10 μM) prevents the production of IFNβ in macrophages^[1].
MRT67307 (10 μM) is sufficient to reduce phospho-ATG13 to control levels^[2].
MRT67307 (10 μM) blocks autophagy in mouse embryonic fibroblasts (MEFs)^[2].
MRT67307 (5 μM; 4 h) abrogates TBK1/IKKε-induced CYLD phosphorylation in 293T cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

293T cells
Concentration:

5 µM
Incubation Time:

4 hours
Result:

Abrogated TBK1/IKKε-induced CYLD phosphorylation.

Chemical Information

CAS. Nr. 1190378-57-4
Appearance Solid
Molecular Weight 464.60
Formel C₂₆H₃₆N₆O₂
Color Off-white to light yellow
SMILES

O=C(NCCCNC1=NC(NC2=CC=CC(CN3CCOCC3)=C2)=NC=C1C4CC4)C5CCC5
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (29)

All WBCell Imaging/Staining

Sort by:

Journal Impact Factor

Nature

Targeting TBK1 to overcome resistance to cancer immunotherapy. [Abstract]

2023 Mar;615(7950):158-167. PMID: 36634707
Nat Med

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. [Abstract]

2018 Aug;24(8):1143-1150. PMID: 30038220

MRT67307 purchased from MedChemExpress. Usage Cited in: Nat Med. 2018 Aug;24(8):1143-1150. [Abstract]

Immunoblot of pSTAT1, STAT1 and β-actin levels in H69AR cells±200 ng/mL IFNg 10 min pulse followed by 24 h chase in media with DMSO, Ruxolitinib (100 nM) or MRT67307 (1 µM).
Cell Res

Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. [Abstract]

2019 Mar;29(3):193-205. PMID: 30651583
Nat Cell Biol

DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Dec;27(12):2143-2151. PMID: 41249572

MRT67307 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Dec;27(12):2143-2151. [Abstract]

Total STAT1 levels in A375 persister cells cotreated for 14 days with 1 μM TBK1 inhibitor MRT67307 (TBK1i) or 1 μM JAKi.
Autophagy

Regulation of pexophagy by a novel TBK1-MARCHF7-PXMP4-NBR1 axis in PEX1-depleted HeLa cells. [Abstract]

2026 Feb;22(2):316-329. PMID: 41267209
Nat Commun

Activation of lysophagy by a TBK1-SCFFBXO3-TMEM192-TAX1BP1 axis in response to lysosomal damage. [Abstract]

2025 Jan 28;16(1):1109. PMID: 39875384

MRT67307 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 28;16(1):1109. [Abstract]

HepG2/GFP-Gal3 cells were treated with either MRT67307 (2 µM) or GSK8612 (10 µM) in combination with LLOMe (750 µM). After the 2-h treatment, LLOMe was washed out with normal cell culture media, and the cells were further incubated with either MRT67307 or GSK8612 for 24 h. The number of GFP-Gal3 puncta was quantified.

MRT67307 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 28;16(1):1109. [Abstract]

HepG2 cells were transfected with both HA-ubiquitin and TMEM192-FLAG and pretreated with either MRT67307 (MRT, 2 µM) or GSK8612 (10 µM). LLOMe was cotreated for an additional 2 h. Subsequently, the cells were immunoprecipitated with agarose bead-conjugated anti-FLAG antibody and further analyzed by western blotting using the indicated antibodies. The results demonstrate that treatment with the TBK1 inhibitor MRT67307 (MRT) attenuated the LLOMe-induced increase in TMEM192 ubiquitination levels.
Nat Commun

Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection. [Abstract]

2023 Sep 18;14(1):5666. PMID: 37723181
Nat Commun

Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. [Abstract]

2015 Jan 21:6:6074. PMID: 25606824

MRT67307 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2015 Jan 21:6:6074. [Abstract]

MRT67307 efficiently inhibited the AKT degradation. IB analysis using WT CD4⁺ T cells, pretreated for 1 h with a TBK1 inhibitor, MRT67307, of solvent control DMSO and subsequently stimulated for the indicated times with anti-CD3 plus anti-CD28 in the presence of a protein synthesis inhibitor, Cycloheximide.
Mol Cell

TBK1-Mediated DRP1 Targeting Confers Nucleic Acid Sensing to Reprogram Mitochondrial Dynamics and Physiology. [Abstract]

2020 Dec 3;80(5):810-827.e7. PMID: 33171123
Theranostics

Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling. [Abstract]

2018 Sep 9;8(17):4633-4648. PMID: 30279728
Cell Chem Biol

Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]

2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599
Int J Mol Med

Quercetin inhibits NTHi-triggered CXCR4 activation through suppressing IKKα/NF-κB and MAPK signaling pathways in otitis media. [Abstract]

2018 Jul;42(1):248-258. PMID: 29568908
Blood Adv

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. [Abstract]

2018 Dec 11;2(23):3428-3442. PMID: 30504235
Mol Ther Methods Clin Dev

Enhanced B cell electroporation efficiency via inhibition of DNA-induced apoptosis and pyroptosis with pan-caspase inhibitor. [Abstract]

2025 Jul 28;33(3):101542. PMID: 40821855
Sci Rep

Pseudomonas aeruginosa-derived DnaJ functions as a novel immunomodulator inducing IFNβ via CME-SGK1-IRF3 axis in macrophages. [Abstract]

2025 Dec 3. PMID: 41339751
iScience

2026 Jul 10;29(8):116736. PMID: 42555398
Clin Immunol

Development and validation of a flow cytometry-based ISG15 induction assay to monitor the type I interferon response. [Abstract]

2026 Feb:283:110654. PMID: 41344526
Biochem J

Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2). [Abstract]

2019 Mar 12;476(5):875-887. PMID: 30782972
Mol Immunol

DNA damage-triggered activation of cGAS-STING pathway induces apoptosis in human keratinocyte HaCaT cells. [Abstract]

2021 Mar:131:180-190. PMID: 33423764
J Immunol Res

c-Myb Dominates TBK1-Mediated Endotoxin Tolerance in Kupffer Cells by Negatively Regulating DTX4. [Abstract]

2023 Mar 31:2023:5990156. PMID: 37032653
bioRxiv

2026 Mar 12.
bioRxiv

DFFB suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Aug 21:2025.08.15.670603. PMID: 40894800
bioRxiv

2025 January 22.
Patent

US20220305048A1.
Patent

US20210025893A1.
Patent

US20200246435A1.
Harvard Medical School

2018 June 13.
Patent

US9814741B2.
Patent

US20150202223A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (215.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1524 mL

10.7619 mL

21.5239 mL

5 mM

0.4305 mL

2.1524 mL

4.3048 mL

10 mM

0.2152 mL

1.0762 mL

2.1524 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Clark K, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. [Content Brief]

[2]. Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015 May 1;290(18):11376-83. [Content Brief]

[3]. Zhu Z, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. 26.37Cancer Discov. 2014 Apr;4(4):452-65. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1524 mL	10.7619 mL	21.5239 mL	53.8097 mL
	5 mM	0.4305 mL	2.1524 mL	4.3048 mL	10.7619 mL
	10 mM	0.2152 mL	1.0762 mL	2.1524 mL	5.3810 mL
	15 mM	0.1435 mL	0.7175 mL	1.4349 mL	3.5873 mL
	20 mM	0.1076 mL	0.5381 mL	1.0762 mL	2.6905 mL
	25 mM	0.0861 mL	0.4305 mL	0.8610 mL	2.1524 mL
	30 mM	0.0717 mL	0.3587 mL	0.7175 mL	1.7937 mL
	40 mM	0.0538 mL	0.2690 mL	0.5381 mL	1.3452 mL
	50 mM	0.0430 mL	0.2152 mL	0.4305 mL	1.0762 mL
	60 mM	0.0359 mL	0.1794 mL	0.3587 mL	0.8968 mL
	80 mM	0.0269 mL	0.1345 mL	0.2690 mL	0.6726 mL
	100 mM	0.0215 mL	0.1076 mL	0.2152 mL	0.5381 mL

Bioz

Keywords

MRT67307

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MRT67307

Publications Citing Use of MedChemExpress (MCE) MRT67307

Alle IKK Isoform-spezifische Produkte anzeigen

Alle ULK Isoform-spezifische Produkte anzeigen